H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Krystal Biotech (KRYS) to $240 from $221 and keeps a Buy rating on the shares based on an adjustment to its base year, an adjustment to the fully diluted share count, increasing its projected odds of success for Vyjuvek to 100% from 95% and increasing projected peak sales expectations in the EU to $600M from $500M.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue